J&J and Basilea End Ceftobiprole Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The news is, on the whole, good for Basilea, but questions remain on how the separation will actually work.
You may also be interested in...
CROs Look Towards Pre-Emptive Standards As FDA Guidance Looms
Some contract research organizations could install new oversight procedures in a pre-emptive move as FDA contemplates its first guidance to regulate the industry
CROs Look Towards Pre-Emptive Standards As FDA Guidance Looms
Some contract research organizations could install new oversight procedures in a pre-emptive move as FDA contemplates its first guidance to regulate the industry
Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up
Switzerland's Basilea licensed its Phase III anti-fungal isavuconazole to Japan's Astellas Pharma Feb. 24, just days after Johnson & Johnson revealed it was pulling out of its five-year deal with the biotech on the delayed antibiotic ceftobiprole